Jubilant Biosys

Delivering the Added Dimension in Drug Discovery Services

In-vivo Pharmacology

The In-vivo Pharmacology & Biology department at Jubilant has state-of-the-art infrastructure and the expertise to conduct PK-PD and efficacy studies in various disease models related to oncology, metabolic disorder, pain, inflammation and respiratory disease therapeutic areas.

Immunocompromised strains of mice, rodents and rabbits are housed in our dedicated animal facility for in-vivo pharmacology. Animal studies for in-vivo pharmacology are conducted under the guidance of the Institutional Ethics Committee and are overseen by experts in each of the models and disease areas.

Inflammation In-Vivo Animal Models

Experimental Autoimmune & Cytokine induced Uveitis Models

  • Rat (IRBP R16), Rabbit (IFNg)

Glaucoma Model

  • Bleomycin-induced glaucoma in rabbits (Target engagement model)

Respiratory Model

  • Lung target engagement in mice (Cytokine induced pSTATs)

Fibrosis Models

  • Lung fibrosis in mice (LPS/Bleomycin)

Inflammatory Bowel Disease Models

  • DSS & Oxazolone-induced Ulcerative Colitis in mice

Arthritis Model

  • Collagen induced arthritis (CIA)

Skin Models

  • TPA induced contact dermatitis
  • Oxazolone induced allergic contact dermatitis
  • Imiquimod induced psoriasis

Pain and Neuroscience In-Vivo Animal Models

Neuropathic Pain Models

  • CCI/SNI models (rats & mice)
  • SNL model
  • Formalin induced phase II response
  • Capsaicin induced secondary sensitization and flinching

Disease Specific Pain Models

  • Chemotherapy induced mechanical allodynia
  • Bone cancer pain model
  • Streptozotocin induced diabetic neuropathy
  • Post – operative pain model

Inflammatory Pain Models

  • CFA induced mechanical hyperalgesia

Alzheimer’s Disease / neurodegeneration Models

  • ICV Injection of Aβ and tau
    • Stereotaxic surgeries
  • Aβ measurement from plasma and CSF
  • Total and phosphotau measurement (ex-vivo)
  • Unfolded protein response (UPR)studies in brain: tunicamycin, thapsigargin induced UPR measurement using stress markers or de novo protein synthesis
  • Stroke model (stress markers and de novo protein synthesis)
  • Novel object recognition test
  • PK-PD Correlations using free tissue and brain concentrations
  • Experience in target validation and development of target engagement models

Diabetes and Metabolic Disorders

Glucose tolerance test in rat and mice

  • Oral
  • Intraperitoneal
  • Intravenous

Pyruvate tolerance test

Insulin tolerance Test

Genetic disease models of diabetes

  • ZDF rats
  • ob/ob mice
  • db/db mice

DIO models

  • Rat
  • Mice
  • nSTZ-HFD fed NASH mice model
  • CDA-HFD NASH model
  • NAFLD mouse model
  • STZ induced diabetic model in mice and rats
  • STZ induced diabetic nephropathy in mice and rats
  • GI emptying model in mice

Oncology

Xenograft Solid Tumor Models

  • Pancreatic cancer (MiaPaCa2 & BxPC3)
  • Lung cancer (A549)
  • Gastric cancer (SNU-5 & Hs746T)
  • Colon cancer (HCT116 & LoVo)
  • Prostate cancer (PC3 & DU145)
  • Ovarian cancer (A2780)
  • Breast cancer (MCF7)
  • Melanoma cancer (A375)

Xenograft Liquid Tumor Models

  • Multiple Myeloma (MM1.S & MM1.R)
  • Acute Myeloid Lymphoma (OCI-AML-3)
  • Chronic Myeloid Leukemia (K562)
  • Mantle Cell Lymphoma (Z138 & MINO)
  • Erythroleukemia (HEL 92.1.7)
  • B Myelomonocytic Leukemia (MV-4-11) Orthotopic Xenograft Models
  • Glioblastoma (U87-MG)

Subcutaneous Syngeneic Models

  • Colon Cancer (CT26)
  • Melanoma Cancer (B16F10)
  • Breast Cancer (4T1)
  • Kidney Cancer (Renca)
  • Lung Cancer (KLN205 & LL/2 (LLC1))
  • Pancreatic Cancer (LTPA)

Orthotopic Syngenic Tumor Model

  • Breast Cancer (4T1)
  • Kidney Cancer (Renca)